# Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects

> **NCT02040090** · PHASE2,PHASE3 · COMPLETED · sponsor: **Kamada, Ltd.** · enrollment: 118 (actual)

## Conditions studied

- Rabies

## Interventions

- **DRUG:** Active rabies vaccine (US-FDA approved)

## Key facts

- **NCT ID:** NCT02040090
- **Lead sponsor:** Kamada, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2021-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02040090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02040090, "Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02040090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*